OGI Bio secures £650k in follow-up funding to expand market presence

OGI Bio specialises in developing innovative solutions for microbial growth and analysis. The company focuses on creating advanced bioreactors and

Facebook
LinkedIn
X

OGI Bio specialises in developing innovative solutions for microbial growth and analysis. The company focuses on creating advanced bioreactors and automated systems that enhance the efficiency and precision of microbial growth.

By integrating cutting-edge technology and automation, OGI Bio facilitates product development in fields such as health and beauty, food manufacturing, feedstock, and green alternatives to petrochemicals. The company’s solutions optimise microbial workflows, reduce labour costs, and increase reproducibility from the earliest stages of product development.

OGI Bio was founded to overcome the challenges of time-consuming manual microbial growth. Unable to afford expensive automation solutions, the founders created and built their own systems from scratch.

“With this investment, we will be launching additional modules to complement our existing market offerings and an enhanced software package that provides our customers with greater flexibility in process control. This will allow them to view, measure, and control their culturing processes from anywhere in the world.” said Alex McVey, CEO of OGI Bio. 

“TRICAPITAL Angels has been a crucial partner for OGI Bio since March 2022, leading the company’s first pre-seed raise alongside partners, including long-term backers Apollo Informal Investments. Over the past two years, TRICAPITAL Angels has continued to provide unwavering support, participating in two further financing rounds.“ McVey added.

TRICAPITAL Angels CEO Moray Martin commented, “TRICAPITAL Angels is proud to continue our support for OGI Bio. Their innovative approach to microbial growth and analysis is transforming the biotechnology industry, and we believe they are well-positioned for significant growth.”

Related Stories from Silicon Scotland

digitizing drug development process
Strathclyde Uni project aims to digitise drug development
Distillery announces long-term partnership with biotech firm
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
CMR Surgical Strengthens Senior Team
Pneumagen highlights broad-spectrum antiviral activity of first-in-class intranasal drug neumifil in new publication

Other Stories from Silicon Scotland